Hypera S.A. (BST:HM6A)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.83B +19.2% |
| Revenue (ttm) | 1.49B +32.4% |
| Net Income | 295.36M +136.2% |
| EPS | 0.45 +127.9% |
| Shares Out | n/a |
| PE Ratio | 9.58 |
| Forward PE | 8.31 |
| Dividend | 0.15 (4.11%) |
| Ex-Dividend Date | Jul 6, 2026 |
| Volume | n/a |
| Open | 3.800 |
| Previous Close | 3.940 |
| Day's Range | 3.660 - 3.840 |
| 52-Week Range | 2.980 - 4.380 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 27, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic... [Read more]
Financial Performance
In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.
Financial numbers in BRL Financial StatementsNews
Hypera upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs upgraded Hypera (HYPMY) to Buy from Neutral with a price target of R$26, up from R$25. After a quarter of solid free cash flow generation in Q2 on…
Hypera Earnings Call Transcript: Q2 2026
Q2 2026 saw robust revenue, EBITDA, and net income growth, with strong cash flow and reduced net debt. New launches in GLP-1 and women's health are set to drive future growth, while working capital and margin improvements are expected to continue.
Hypera Document: Q2 2026
Hypera filed a regulatory document on August 7, 2026 disclosing important business information.
Hypera Earnings release: Q2 2026
Hypera released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
Hypera Slides: Q2 2026
Hypera has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 7, 2026.
Hypera initiated with a Buy at Jefferies
Jefferies initiated coverage of Hypera (HYPMY) with a Buy rating and R$28.70 price target The firm names Hypera its preferred name in Latin America pharma, saying the company company offers…
Hypera upgraded to Buy from Neutral at Citi
Citi analyst Leandro Bastos upgraded Hypera (HYPMY) to Buy from Neutral with a price target of R$28, up from R$26. The firm cites the company’s stricter working capital conditions and…
Hypera Earnings Call Transcript: Q1 2026
Q1 2026 saw 87% revenue growth and 9.5% sell-out increase, driven by new launches and logistics gains. Net debt fell nearly 20% after a BRL 1.5 billion capital increase, with strong cash flow and margin performance. Outlook remains positive, with further launches and inventory optimization expected.
Hypera Earnings release: Q1 2026
Hypera released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Hypera Slides: Q1 2026
Hypera has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Hypera Document: Q1 2026
Hypera filed a regulatory document on April 28, 2026 disclosing important business information.
Hypera Slides: Corporate presentation
Hypera has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Hypera Earnings Call Transcript: Q4 2025
Sellout grew 6.8% in 2025, with net revenue up 3.4% and record operating cash flow after working capital optimization. Entering 2026, the company expects further efficiency gains, strong cash flow, and growth from new launches, especially semaglutide, pending regulatory approval.
Hypera Earnings release: Q4 2025
Hypera released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
Hypera Slides: Q4 2025
Hypera has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 13, 2026.
Hypera Earnings Call Transcript: Q3 2025
Net revenue rose 16% year-over-year to BRL 2.2 billion, with EBITDA margin at 34% and record operational cash flow. Retail outperformed the market, while institutional sales declined; strong pipeline and new launches are expected to drive future growth.
Hypera Earnings release: Q3 2025
Hypera released its Q3 2025 earnings on October 28, 2025, summarizing the period's financial results.
Hypera Slides: Q3 2025
Hypera has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 28, 2025.
Hypera Document: Q3 2025
Hypera filed a regulatory document on October 28, 2025 disclosing important business information.
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.
Hypera confirms acquisition proposal received from EMS
Hypera (HYPMY) Pharma, in compliance with current regulations, informs that on this date it received a proposal for a public offer for the acquisition of shares and a combination of…
EMS offers to buy Hypera for R$30 per share, Brazil Journal reports
EMS has proposed a merger with Hypera (HYPMY) in a deal that would create Brazil’s biggest pharmaceutical player, Pedro Arbex of Brazil Journal reports, citing people familiar with the matter.
Hypera downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Gustavo Miele downgraded Hypera to Neutral from Buy with a price target of R$37, down from R$39. In a nutshell, the firm is incrementally more cautious on…
Hypera downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Javier Martinez de Olcoz Cerdan downgraded Hypera to Equal Weight from Overweight with an unchanged price target of R$47.20. 2022 was a great year for revenue and…